In what was generally considered a negative earnings report release the firm tried to dust off the negative news with some non GAAP future and past angles but there is no denying that the price of the stock has been steadily falling since 2015. Gilead makes its living fighting HIV. By most measure the product are well accepted and established in the market, but the firm consistently misses its targets and has fallen form a high on 2015 of 123 to today’s price of 66.
Eurozone Weakness
Daily Analysis - 03/05/2018